Join

Compare · MURF vs NVS

MURF vs NVS

Side-by-side comparison of Murphy Canyon Acquisition Corp. (MURF) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MURF and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS carries a market cap of $277.58B.
  • NVS has more recent analyst coverage (25 ratings vs 0 for MURF).
MetricMURFNVS
Company
Murphy Canyon Acquisition Corp.
Novartis AG
Price
$17.48-1.52%
$145.43-1.37%
Market cap
-
$277.58B
1M return
-
-3.48%
1Y return
-
+29.12%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2022
News (4w)
0
0
Recent ratings
0
25
MURF

Murphy Canyon Acquisition Corp.

Murphy Canyon Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on identifying businesses in the real estate industry, including construction, homebuilding, real estate owners and operators, arrangers of financing, insurance, and other services for real estate, and adjacent businesses and technologies targeting the real estate space. The company was incorporated in 2021 and is based in San Diego, California.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.